Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489430 | 0.82 | USP30 (0.47) | KDM4EUSP30HRH4 | |
| SCHEMBL4200961 | 0.81 | ACHE (0.50) | HRH3OPRM1KDM4EHTR1A | |
| SCHEMBL4166257 | 0.80 | ACVR1 (0.44) | HRH3HRH1HRH4 | |
| SCHEMBL15511394 | 0.79 | HRH4 (0.54) | KDM4EADRA2CHRH4TP53BP1 | |
| SCHEMBL4177089 | 0.77 | HRH3 (0.53) | HRH3KDM4E | |
| SCHEMBL4168169 | 0.77 | HRH4 (0.44) | HRH3POLBHTR1AHRH1HRH4 | |
| Cyclopropane SCHEMBL4949151 | 0.77 | HRH4 (0.48) | HRH3KDM4ENR3C2HTR1AADRA2C | |
| Cyclopentane SCHEMBL4948650 | 0.77 | HRH4 (0.48) | HRH3KDM4ENR3C2HTR1AADRA2C | |
| Cyclohexane SCHEMBL4949527 | 0.77 | HRH4 (0.48) | HRH3KDM4ENR3C2HTR1AADRA2C | |
| SCHEMBL2563048 | 0.77 | USP30 (0.39) | OPRM1USP30TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | claimed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | claimed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | claimed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | claimed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-7612076-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | NETTEKOVEN MATTHIAS HEINRICH | 2009-02-12 | — | — | US | disclosed |
| US-7456175-B2 | Piperazinyl-pyridine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1828134-B1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | HOFFMANN LA ROCHE (CH) | 2008-10-29 | — | — | EP | disclosed |
| EP-1828134-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063718-A1 | PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135528-A1 | Piperazinyl-pyridine derivatives | HRH4, HRH3, H1-3 | HRH3 2/4885OPRM1 75/4885KDM4E 541/4885 |
| US-20090042903-A1 | PIPERAZINYL-PYRIDINE DERIVATIVES | HRH4, HRH3, H1-3 | HRH3 2/4885OPRM1 75/4885KDM4E 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.